Anthropometric indexes, insulin resistance, and serum leptin and lipid levels in women with cryptogenic epilepsy receiving topiramate treatment

被引:15
作者
Genc, Bulent Oguz [1 ]
Dogan, Ebru Apaydin [1 ]
Dogan, Umuttan [2 ]
Genc, Emine [1 ]
机构
[1] Selcuk Univ, Meram Sch Med, Dept Neurol, Ana Bilim Dali, TR-42080 Meram Konya, Turkey
[2] Selcuk Univ, Meram Sch Med, Dept Cardiol, TR-42080 Meram Konya, Turkey
关键词
Body mass index; HDL cholesterol; Insulin resistance; Leptin topiramate; Waist circumference; HOMEOSTASIS MODEL ASSESSMENT; ANTIEPILEPTIC DRUGS; WEIGHT-LOSS; RISK-FACTORS; DOUBLE-BLIND; BODY-WEIGHT; CARBAMAZEPINE; LIPOPROTEINS; MORTALITY; CHILDREN;
D O I
10.1016/j.jocn.2010.01.045
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
We aimed to investigate the effects of topiramate monotherapy on anthropometric indexes, insulin resistance, and serum leptin and lipid levels in 33 premenopausal women (mean age +/- standard deviation: 26.7 +/- 7.1 years) with cryptogenic epilepsy. Body mass index (BMI), waist circumference and serum leptin, insulin and lipid levels were measured at baseline and at 6 months after initiation of topiramate. We found reductions in BMI (p < 0.001), waist circumference (p < 0.001) and serum high-density lipoprotein (HDL) cholesterol levels (p = 0.011). We also found significant improvements in insulin resistance (p = 0.023), but not in serum leptin levels (p = 0.45). Our results suggest that topiramate treatment in women with epilepsy is associated with reduced BMI and waist circumference and improvement in insulin resistance; however, according to our data, topiramate treatment is also associated with lower HDL cholesterol levels, which may substantially increase vascular disease. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1256 / 1259
页数:4
相关论文
共 31 条
[1]
The metabolic syndrome - a new worldwide definition [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
LANCET, 2005, 366 (9491) :1059-1062
[2]
HEART-DISEASE MORTALITY AND MORBIDITY IN PATIENTS WITH EPILEPSY [J].
ANNEGERS, JF ;
HAUSER, WA ;
SHIRTS, SB .
EPILEPSIA, 1984, 25 (06) :699-704
[3]
[4]
Predictors of weight loss in adults with topiramate-treated epilepsy [J].
Ben-Menachem, E ;
Axelsen, M ;
Johanson, EH ;
Stagge, A ;
Smith, U .
OBESITY RESEARCH, 2003, 11 (04) :556-562
[5]
Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity - Studies in subjects with various degrees of glucose tolerance and insulin sensitivity [J].
Bonora, E ;
Saggiani, F ;
Targher, G ;
Zenere, MB ;
Alberiche, M ;
Monauni, T ;
Bonadonna, RC ;
Muggeo, M .
DIABETES CARE, 2000, 23 (01) :57-63
[6]
A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity [J].
Bray, GA ;
Hollander, P ;
Klein, S ;
Kushner, R ;
Levy, B ;
Fitchet, M ;
Perry, BH .
OBESITY RESEARCH, 2003, 11 (06) :722-733
[7]
SERUM-LIPIDS, LIPOPROTEINS AND APOLIPOPROTEIN-A AND APOLIPOPROTEIN-B IN EPILEPTIC PATIENTS TREATED WITH VALPROIC ACID, CARBAMAZEPINE OR PHENOBARBITAL [J].
CALANDRE, EP ;
RODRIGUEZLOPEZ, C ;
BLAZQUEZ, A ;
CANO, D .
ACTA NEUROLOGICA SCANDINAVICA, 1991, 83 (04) :250-253
[8]
EFFECTS OF LONG-TERM TREATMENT WITH ANTIEPILEPTIC DRUGS ON SERUM-LIPID LEVELS IN CHILDREN WITH EPILEPSY [J].
EIRIS, JM ;
LOJO, S ;
DELRIO, MC ;
NOVO, I ;
BRAVO, M ;
PAVON, P ;
CASTROGAGO, M .
NEUROLOGY, 1995, 45 (06) :1155-1157
[9]
Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients:: randomized double-blind placebo-controlled trial [J].
Eliasson, B. ;
Gudbjornsdottir, S. ;
Liang, Y. ;
Vercruysse, F. ;
Smith, U. .
INTERNATIONAL JOURNAL OF OBESITY, 2007, 31 (07) :1140-1147
[10]
FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1